PTGX - Latest News

Protagonist Therapeutics, Inc. (PTGX), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $6.68B. Beta to the broader market is 1.88.

The article list below shows the most recent PTGX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent PTGX Headlines

Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy

zacks.com - May 12, 2026

JNJ bets on Tremfya and newly approved Icotyde to drive immunology growth as Stelara faces biosimilar pressure.

Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update

accessnewswire.com - May 5, 2026

ICOTYDE™ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment; Protagonist recei

Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

accessnewswire.com - Apr 28, 2026

Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA approval of rusfertide for polycyth

Protagonist Therapeutics Reports Granting of Inducement Awards

accessnewswire.com - Apr 16, 2026

NEWARK, CA / ACCESS Newswire / April 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on April 15, 2026, it issued inducem

SG Americas Securities LLC Sells 21,249 Shares of Protagonist Therapeutics, Inc. $PTGX

defenseworld.net - Apr 6, 2026

SG Americas Securities LLC reduced its holdings in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 51.

How News Affects PTGX Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track PTGX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked PTGX news questions

What is the latest PTGX news headline?

The most recent PTGX headline (May 12, 2026) is "Tremfya, Icotyde Lead J&J's Post-Stelara Immunology Strategy". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the PTGX news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What PTGX news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual PTGX options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.